SSR 150106
Alternative Names: SSR150106; SSR150106XBLatest Information Update: 09 Aug 2019
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Anti-inflammatories
- Mechanism of Action CCR2 receptor antagonists; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postoperative pain; Rheumatoid arthritis
Most Recent Events
- 13 Feb 2007 Phase-II clinical trials in Inflammation in Europe (unspecified route)
- 01 Mar 2005 Phase-I clinical trials in Inflammation in Europe (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis